IS1935B - Fósínópríl lyfjasamsetning - Google Patents

Fósínópríl lyfjasamsetning

Info

Publication number: IS1935B
Authority: IS; Iceland
Prior art keywords: fosinopril; pharmaceutical composition; formulation; fosinoprilat; ace
Prior art date: 2002-03-19

Application number

IS6315A

Other languages

English (en)

Other versions

IS6315A (is

Inventor

Eyjolfsson Reynir

Original Assignee

Actavis Group Hf.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-19

Filing date

2002-03-19

Publication date

2004-06-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36715398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS1935(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-19 Application filed by Actavis Group Hf. filed Critical Actavis Group Hf.

2002-03-19 Priority to IS6315A priority Critical patent/IS1935B/is

2003-03-19 Priority to AU2003208599A priority patent/AU2003208599A1/en

2003-03-19 Priority to DE60303041T priority patent/DE60303041T2/de

2003-03-19 Priority to DK03706893T priority patent/DK1531831T3/da

2003-03-19 Priority to EP03706893A priority patent/EP1531831B1/en

2003-03-19 Priority to US10/507,918 priority patent/US7045511B2/en

2003-03-19 Priority to ES03706893T priority patent/ES2256721T3/es

2003-03-19 Priority to UA20041008392A priority patent/UA78988C2/uk

2003-03-19 Priority to PT03706893T priority patent/PT1531831E/pt

2003-03-19 Priority to AT03706893T priority patent/ATE314076T1/de

2003-03-19 Priority to PCT/IS2003/000013 priority patent/WO2003077929A1/en

2003-03-19 Priority to EA200401218A priority patent/EA008171B1/ru

2003-09-20 Publication of IS6315A publication Critical patent/IS6315A/is

2004-06-16 Publication of IS1935B publication Critical patent/IS1935B/is

2004-10-18 Priority to NO20044390A priority patent/NO20044390L/no

Links

BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 title abstract 3
229960002490 fosinopril Drugs 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
238000009472 formulation Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
WOIWWYDXDVSWAZ-RTWAWAEBSA-N fosinoprilat Chemical compound C([C@@H](C[C@H]1C(=O)O)C2CCCCC2)N1C(=O)CP(O)(=O)CCCCC1=CC=CC=C1 WOIWWYDXDVSWAZ-RTWAWAEBSA-N 0.000 abstract 1
229960003018 fosinoprilat Drugs 0.000 abstract 1
239000000314 lubricant Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IS6315A 2002-03-19 2002-03-19 Fósínópríl lyfjasamsetning IS1935B (is)

Priority Applications (13)

Application Number	Priority Date	Filing Date	Title
IS6315A IS1935B (is)	2002-03-19	2002-03-19	Fósínópríl lyfjasamsetning
EA200401218A EA008171B1 (ru)	2002-03-19	2003-03-19	Фармацевтическая композиция, содержащая фозиноприл
ES03706893T ES2256721T3 (es)	2002-03-19	2003-03-19	Formulacion de fosinopril.
PT03706893T PT1531831E (pt)	2002-03-19	2003-03-19	Formulacao de fosinopril
DK03706893T DK1531831T3 (da)	2002-03-19	2003-03-19	Fosinoprilformulering
EP03706893A EP1531831B1 (en)	2002-03-19	2003-03-19	Fosinopril formulation
US10/507,918 US7045511B2 (en)	2002-03-19	2003-03-19	Fosinopril formulation
AU2003208599A AU2003208599A1 (en)	2002-03-19	2003-03-19	Fosinopril formulation
UA20041008392A UA78988C2 (en)	2002-03-19	2003-03-19	Pharmaceutical formulation comprising fosinopril
DE60303041T DE60303041T2 (de)	2002-03-19	2003-03-19	Fosinopril-formulierung
AT03706893T ATE314076T1 (de)	2002-03-19	2003-03-19	Fosinopril-formulierung
PCT/IS2003/000013 WO2003077929A1 (en)	2002-03-19	2003-03-19	Fosinopril formulation
NO20044390A NO20044390L (no)	2002-03-19	2004-10-18	Fosinoprilformulering

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IS6315A IS1935B (is)	2002-03-19	2002-03-19	Fósínópríl lyfjasamsetning

Publications (2)

Publication Number	Publication Date
IS6315A IS6315A (is)	2003-09-20
IS1935B true IS1935B (is)	2004-06-16

Family

ID=36715398

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6315A IS1935B (is)	2002-03-19	2002-03-19	Fósínópríl lyfjasamsetning

Country Status (13)

Country	Link
US (1)	US7045511B2 (is)
EP (1)	EP1531831B1 (is)
AT (1)	ATE314076T1 (is)
AU (1)	AU2003208599A1 (is)
DE (1)	DE60303041T2 (is)
DK (1)	DK1531831T3 (is)
EA (1)	EA008171B1 (is)
ES (1)	ES2256721T3 (is)
IS (1)	IS1935B (is)
NO (1)	NO20044390L (is)
PT (1)	PT1531831E (is)
UA (1)	UA78988C2 (is)
WO (1)	WO2003077929A1 (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2322854T3 (es) *	2003-06-26	2009-06-30	Teva Pharmaceutical Industries Limited	Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo(3.3.0)-octano-3-carboxilico.
US20050095287A1 (en) *	2003-10-29	2005-05-05	Matharu Amol S.	Fosinopril composition
GB2411355B (en) *	2004-02-27	2006-02-22	Niche Generics Ltd	Pharmaceutical composition
MX2007008392A (es) *	2005-02-11	2007-09-06	Aventis Pharma Inc	Esteres de acido propano-fosfinico sustituido.
WO2006100602A2 (en) *	2005-03-22	2006-09-28	Aurobindo Pharma Ltd	Immediate release stable solid oral dosage forms op fosinopril
KR20080112387A (ko) *	2006-04-19	2008-12-24	테바 파마슈티컬 인더스트리즈 리미티드	2-아자-비사이클로[3.3.0]-옥탄-3-카르복실산 유도체의 안정한 약학 조성물
GB0612540D0 (en) *	2006-06-23	2006-08-02	Novartis Ag	Galenical formulations of organic compounds
ATE406173T1 (de) *	2006-07-10	2008-09-15	Teva Pharma	Stabile zubereitung enthaltend eine kombination aus einer feuchtigkeitsempfindlichen aktiven substanz und einer zweiten aktiven substanz und verfahren zur herstellung der zubereitung.
US20140179712A1 (en)	2012-12-21	2014-06-26	Astrazeneca Ab	Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4337201A (en) *	1980-12-04	1982-06-29	E. R. Squibb & Sons, Inc.	Phosphinylalkanoyl substituted prolines
US5006344A (en)	1989-07-10	1991-04-09	E. R. Squibb & Sons, Inc.	Fosinopril tablet formulations
US6521647B2 (en) *	2000-04-04	2003-02-18	Pfizer Inc.	Treatment of renal disorders
CA2330904C (en) *	2001-01-11	2006-10-24	Bernard Charles Sherman	Fosinopril sodium tablet formulation
JP2005508978A (ja) *	2001-11-02	2005-04-07	ファイザー・プロダクツ・インク	Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
ITMI20012366A1 (it) *	2001-11-09	2003-05-09	Farmatron Ltd	Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali

2002
- 2002-03-19 IS IS6315A patent/IS1935B/is unknown
2003
- 2003-03-19 DE DE60303041T patent/DE60303041T2/de not_active Expired - Lifetime
- 2003-03-19 AT AT03706893T patent/ATE314076T1/de active
- 2003-03-19 EA EA200401218A patent/EA008171B1/ru not_active IP Right Cessation
- 2003-03-19 WO PCT/IS2003/000013 patent/WO2003077929A1/en not_active Ceased
- 2003-03-19 ES ES03706893T patent/ES2256721T3/es not_active Expired - Lifetime
- 2003-03-19 AU AU2003208599A patent/AU2003208599A1/en not_active Abandoned
- 2003-03-19 DK DK03706893T patent/DK1531831T3/da active
- 2003-03-19 US US10/507,918 patent/US7045511B2/en not_active Expired - Fee Related
- 2003-03-19 PT PT03706893T patent/PT1531831E/pt unknown
- 2003-03-19 UA UA20041008392A patent/UA78988C2/uk unknown
- 2003-03-19 EP EP03706893A patent/EP1531831B1/en not_active Expired - Lifetime
2004
- 2004-10-18 NO NO20044390A patent/NO20044390L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ES2256721T3 (es)	2006-07-16
US7045511B2 (en)	2006-05-16
EP1531831A1 (en)	2005-05-25
DK1531831T3 (da)	2006-05-15
US20050256086A1 (en)	2005-11-17
IS6315A (is)	2003-09-20
UA78988C2 (en)	2007-05-10
WO2003077929A1 (en)	2003-09-25
NO20044390L (no)	2004-12-15
PT1531831E (pt)	2006-05-31
EA200401218A1 (ru)	2005-12-29
DE60303041T2 (de)	2006-08-24
DE60303041D1 (de)	2006-02-02
ATE314076T1 (de)	2006-01-15
AU2003208599A1 (en)	2003-09-29
EA008171B1 (ru)	2007-04-27
EP1531831B1 (en)	2005-12-28

Publication	Publication Date	Title
CO5590918A2 (es)	2005-12-30	Formulaciones
CY1109457T1 (el)	2014-08-13	Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει
MXPA04004464A (es)	2004-08-11	Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
MA29854B1 (fr)	2008-10-03	Nouvelle formulation
MY138252A (en)	2009-05-29	Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
SG10201809390QA (en)	2018-11-29	Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MA29857B1 (fr)	2008-10-03	Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
MX2009003926A (es)	2009-06-26	Composiciones de fenilalquilamino-carbamato.
NO20081050L (no)	2008-04-28	Kaspaseinhibitor-prodroger
MY140841A (en)	2010-01-29	Indozolone derivatives as 11b-hsd1 inhibitors
MX2009003929A (es)	2009-06-26	Composiciones de fenilalquil carbamato.
UA89394C2 (uk)	2010-01-25	Композиція оланзапіну або донепезилу, що розпадається при пероральному прийомі
MA29278B1 (fr)	2008-02-01	Composition pharmaceutique comprenant un derive de l'indolylmaleimide
IS6315A (is)	2003-09-20	Fósínópríl lyfjasamsetning
MXPA04006266A (es)	2004-09-27	Pirimidotriazinas como inhibidores de fosfatasa.
BR0311327A (pt)	2005-02-22	Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
BR0112245B1 (pt)	2013-09-10	Éster de ácido 4-alcóxi-ciclohexano-1-amino-carboxílico
EA200601608A1 (ru)	2007-02-27	Способ производства твёрдой фармацевтической композиции
WO2008036316A3 (en)	2008-11-06	Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
ATE464043T1 (de)	2010-04-15	Pharmazeutische zusammensetzung enthaltend l- arginin
IL171992A0 (en)	2011-08-01	Storage-stable fluorescent whitener formulations
WO2006031929A3 (en)	2006-06-01	Thiazolopyridine kinase inhibitors
TW200640860A (en)	2006-12-01	Lercanidipine free base
AU2003202550A1 (en)	2003-07-24	Pharmaceutical formulations with modified release
CY1110814T1 (el)	2015-06-10	Νεα υποκατεστημενα αρυλοεξαδιενικα οξεα και εστερες αυτων τα οποια μπορουν να χρησιμοποιηθουν για την αγωγη και προληψη του διαβητη, δυσλιπιδαιμιας και αθηροσκληρωσης, φαρμακευτικες συνθεσεις που τα περιλαμβανουν και διεργασιες για την παρασκευη αυτων